IL5
Interleukin-5
As of the edition of 20 October 2026, IL5 (interleukin-5, UniProt P05113) has 5 drugs tested at it and 6 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P05113
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 5
- Disease areas
- Lungs and airways; Immune system; Blood and lymph; Skin and connective tissue; Ear, nose and throat; Heart and blood vessels; Digestive system; Infections
- Registered trials of its drugs
- 144
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Active | 2 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Mepolizumab | Marketed | Phase 4 | Ends 2027 |
| Reslizumab | Marketed | Phase 4 | Ends 2028 |
| Depemokimab | Marketed | Phase 4 | Ends 2037 |
| SHR-1703 | Active | Phase 3 | none listed |
| BBT002 | Active | Phase 2 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Engaged | 3 |
| Undetermined | 1 |
| Total on the list | 6 |
The other 4 companies at IL5
In the product6 companies in all; 4 are not named here, and no score is.
See the 6 companies at IL5, ranked, with the facts behind eachRequest access. Nothing is shown until you do.